MedTrace Logo

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine

NCT02426905 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-08-23

No results posted yet for this study

Summary

A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.

Conditions

  • Wilson Disease

Interventions

DRUG

trientine dihydrochloride

A retrospective review of patients' medical records

Sponsors & Collaborators

  • Univar BV

    lead INDUSTRY

Principal Investigators

  • Karl-Heinz Weiss, MD · Universitätsklinik Heidelberg

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-05-31
Completion
2018-07-31

Countries

  • Germany
  • Greece
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426905 on ClinicalTrials.gov